A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex. We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and regenerative medicine.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 371M | - | 915M |
| Net Income | -582M | -582M | -366M | -154M | -650M | 378M |
| EPS | $-6.47 | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Free Cash Flow | -346M | -346M | -145M | -270M | -533M | 457M |
| ROIC | -33.3% | -30.2% | -19.0% | -8.2% | -34.7% | 15.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.18 | 0.16 | 0.18 | 0.20 | 0.15 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -665M | -665M | -467M | -223M | -673M | 374M |
| Operating Margin | 0.0% | - | - | -60.0% | - | 40.8% |
| ROE | -30.3% | -30.2% | -19.0% | -8.2% | -34.7% | 15.7% |
| Shares Outstanding | 90M | 90M | 84M | 79M | 78M | 80M |
CRISPR Therapeutics AG passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +109.8%.
CRISPR Therapeutics AG (CRSP) has a 5-year average return on invested capital (ROIC) of -15.3%. This is below average and may indicate limited pricing power.
CRISPR Therapeutics AG (CRSP) has a market capitalization of $4.9B. It is classified as a mid-cap stock.
CRISPR Therapeutics AG (CRSP) does not currently pay a regular dividend.
CRISPR Therapeutics AG (CRSP) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
CRISPR Therapeutics AG (CRSP) generated $-346 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CRISPR Therapeutics AG (CRSP) has a debt-to-equity ratio of 0.18. This indicates a conservatively financed balance sheet.
CRISPR Therapeutics AG (CRSP) reported earnings per share (EPS) of $-6.47 in its most recent fiscal year.
CRISPR Therapeutics AG (CRSP) has a return on equity (ROE) of -30.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for CRISPR Therapeutics AG (CRSP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CRISPR Therapeutics AG (CRSP) has a book value per share of $21.38, based on its most recent annual SEC filing.